Recor Medical Supports ESC Guidelines for Hypertension Care
Recor Medical Endorses ESC Hypertension Management Guidelines
The recent guidelines updated by the European Society of Cardiology (ESC) for the management of elevated blood pressure were unveiled during the ESC Congress and emphasize the role of renal denervation as a valuable option for treating uncontrolled hypertension.
Palo Alto, California, and Frankfurt am Main, Germany - Recor Medical, Inc. ("Recor") along with its parent company, Otsuka Medical Devices Co., Ltd., have officially endorsed the new recommendations for hypertension management put forth by the ESC. This endorsement highlights the findings presented at the ESC Congress earlier this year, showcasing the importance of considering renal denervation (RDN) for patients suffering from resistant hypertension.
The Impact of Hypertension
Hypertension poses a significant health risk, affecting over one billion people globally, often referred to as a silent killer due to its asymptomatic nature. Many individuals remain unaware of their condition, and despite lifestyle modifications and medications, a considerable number fail to achieve controlled blood pressure levels. Recor’s innovative Paradise™ Ultrasound Renal Denervation (uRDN) system targets the overactive sympathetic nerves surrounding the renal arteries, specifically designed for hypertensive patients not adequately managed by traditional therapies.
Key Developments at the ESC Congress
During the congress, the updated ESC guidelines, titled "2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension," received significant attention. These guidelines recommend RDN as a safe and effective treatment for patients with resistant hypertension, particularly those at higher cardiovascular risk.
Expert Opinions on the New Guidelines
Prof. Dr. Michael Böhm, a noted cardiologist and director of Internal Medicine III at Saarland University Hospital, expressed optimism regarding the new recommendations. He noted, "This guidance signifies a meaningful advancement for patients who need safe and effective hypertension management options when typical lifestyle adjustments and pharmacological treatments fall short." He highlighted the critical need for multidisciplinary approaches in managing renal denervation and encouraged rigorous discussions around risks and benefits with patients.
Clinical Trials Supporting Efficacy
Recor Medical has successfully conducted three global, independently powered, randomized clinical trials involving over 500 patients with uncontrolled hypertension. These trials — RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II — achieved their primary goals of demonstrating significant blood pressure reduction with favorable safety outcomes. The Paradise system has been CE marked since 2012, and Recor is actively collaborating with the cardiology community across Europe to enhance awareness and adoption of ultrasound RDN therapy.
Commitment to Hypertension Management
As Recor President and CEO Lara Barghout stated, "We are thrilled that the ESC guidelines acknowledge renal denervation as an effective treatment for uncontrolled hypertension. The need to tackle this global health challenge remains urgent, and we are dedicated to transforming hypertension management by delivering the benefits of our Paradise system to those who need it most."
Company Overview: Recor Medical, Inc.
Recor Medical is based in Palo Alto, California, and operates as a subsidiary of Otsuka Medical Devices Co., Ltd. The company is on a mission to innovate hypertension management through the development of the Paradise Ultrasound Renal Denervation system. Though still investigational in Japan, this system has received FDA approval in the United States and has earned the CE mark for broader regulatory acceptance in Europe.
About Otsuka Medical Devices
Otsuka Medical Devices Co., Ltd. focuses on advancing medical technologies that provide novel therapeutic options where existing treatments fail. As a subsidiary of Otsuka Holdings Co., Ltd., listed on the Tokyo Stock Exchange, Otsuka Medical Devices brings a global perspective to healthcare innovation.
Frequently Asked Questions
What are the new ESC guidelines for hypertension management?
The updated ESC guidelines emphasize the importance of renal denervation as a treatment for uncontrolled hypertension and highlight its efficacy and safety.
Why is renal denervation important for hypertension treatment?
Renal denervation targets sympathetic nerves that contribute to high blood pressure, helping patients who do not respond to lifestyle changes and medication.
What recent studies support the Paradise uRDN system?
Three independent, randomized clinical trials have demonstrated the effectiveness and safety of the Paradise system in managing resistant hypertension.
Who is Recor Medical?
Recor Medical is a medical technology company focused on hypertension treatment, particularly through its innovative ultrasound renal denervation technology.
How does Recor's technology work?
The Paradise system uses ultrasound energy to disrupt overactive renal nerves, aiming to reduce blood pressure and improve patient health outcomes.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- Coloplast A/S Share Trading Insights for Board and Executives
- BW Offshore Adjusts Convertible Bonds for Shareholders' Dividend
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- CenExel Launches Advanced PET Scan Unit for Research
- Healthcare Mobility Solutions Market Foresees Major Growth
- ChartPath and WoundZoom Partner to Revolutionize Wound Care
- Affiliated Network Providers and Aurora Health Join Forces
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- Steward Healthcare Faces Bankruptcy Challenges Next Week
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Semnur Pharmaceuticals and Denali Capital to Merge for Growth
- ThreatHunter.ai Launches Free Cybersecurity Tool for Businesses
- Kronos Bio to Showcase Research at Key Medical Conferences
- RDE, Inc. Changes Ticker Symbol to GIFT for Growth
- Veterinary Point of Care Diagnostics Market Forecast Growth
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
- Mount Logan Capital Inc. Expands Workforce with New Hire
- Weatherford Strengthens Digital Portfolio with Datagration Deal
- CVRx Expands Board with New Appointments for Growth
- VCI Global Secures $18 Million Contract for IPO Listings
- AITX’s RAD Achieves Record Growth and Revenue in Q2 FY 2025
Recent Articles
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Steward Healthcare Faces Bankruptcy Challenges Next Week
- Coating Additives Market Anticipates Expansive Growth Ahead
- Navigating Spirit Airlines: A Deep Dive Into SAVE's Future
- Strider Bikes Hosts an Exciting Adventure-Cross Race
- Market Insights: Futures Dip Amid Nvidia and Tesla News
- Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
- Amicus Therapeutics to Showcase at Investor Conferences This Fall
- H World Group Limited Appoints New Chief Financial Officer
- Axxess and Transcend Strategy Group Collaborate for Growth
- Invert Joins Toronto International Film Festival as Partner
- Orion Energy Systems to Showcase at H.C. Wainwright Event
- ADC Therapeutics Announces Conference Presentations in September
- Danske Bank A/S Updates on Managerial Transactions - 2024
- Chris Ramirez Joins mesur.io as New VP of Sales to Drive Growth
- Calliditas Therapeutics Announces Corporate Actions with Asahi Kasei
- Viridien Highlights Total Voting Rights and Share Information
- Hudson Valley Cancer Center Partners with New York Cancer Specialists
- Significance of On-Train Internet Connectivity for Rail Future
- AliveDx Achieves IVDR-CE Mark for Groundbreaking Celiac Test
- Lam Research Announces Dividend Increase Amid AI Expansion
- SKF Welcomes Susanne Larsson as Chief Financial Officer
- GC Biopharma Partners with Hanmi to Advance Fabry Treatment
- AMSilk Joins the World Economic Forum's Global Innovators Community